title: Reactive arthritis: a favorable 2 year course and outcome, independent of triggering agent and HLA-B27.
abstract: OBJECTIVE
  To study the 2 year course and clinical and radiological outcome of reactive arthritis and to identify possible outcome predictors.
  
  
  METHODS
  Patients with chlamydia induced arthritis (n = 25) and arthritis induced by enterobacteria (n = 27), all derived from a 2-year epidemiological study on reactive arthritis (ReA) and possible ReA, were followed prospectively with clinical, laboratory and radiographic examinations.
  
  
  RESULTS
  After one year, 40% of patients with chlamydia induced arthritis and 20% of those with enteroarthritis still had clinical signs of arthritis. After 2 years, 100 and 95%, respectively, had recovered. At that time, one patient with enteroarthritis had developed radiographic abnormalities exceeding grade I in peripheral joints. None developed bilateral sacroiliitis during the course. The duration of ReA was found to be independent of the triggering agent, sex, age, duration of arthritis prior to entry, pain, index of active joints, CRP and the presence of HLA-B27.
  
  
  CONCLUSIONS
  Early recognition and elimination of the triggering microbe seems important for the arthritis outcome in ReA. The results do not support the hypothesis that the presence of HLA-B27 heralds a more serious disease course or less favorable outcome, nor that the type of triggering agent predicts the outcome.
authors.affiliation: Oslo City Department of Rheumatology, Norwegian Lutheran Hospital, Oslo.
authors.forename: A
authors.initials: A
authors.lastname: Glennås
authors.forename: T K
authors.initials: TK
authors.lastname: Kvien
authors.forename: K
authors.initials: K
authors.lastname: Melby
authors.forename: A
authors.initials: A
authors.lastname: Overbøo
authors.forename: O
authors.initials: O
authors.lastname: Andrup
authors.forename: B
authors.initials: B
authors.lastname: Karstensen
authors.forename: J E
authors.initials: JE
authors.lastname: Thoen
mesh_terms: D000293:Adolescent; D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000328:Adult; D000367:Age Factors; D000704:Analysis of Variance; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D016918:Arthritis, Reactive / Q000188:drug therapy* / Q000276:immunology / Q000382:microbiology / Q000503:physiopathology; D004359:Drug Therapy, Combination; D005260:Female; D015796:HLA-B27 Antigen / Q000032:analysis*; D006801:Humans; D008297:Male; D008875:Middle Aged; D000091402:Prohibitins; D011446:Prospective Studies; D012737:Sex Factors; D016896:Treatment Outcome
chemical_list: D000305:Adrenal Cortex Hormones; D000900:Anti-Bacterial Agents; D000893:Anti-Inflammatory Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D015796:HLA-B27 Antigen; C000717331:PHB2 protein, human; D000091402:Prohibitins